{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:28:13Z","timestamp":1760236093961,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>A 79-year-old female patient with no pre-existing rheumatological conditions presented with severe functional impairment secondary to polyarthralgia, most likely an adverse reaction following her first dose of Oxford\/AstraZeneca ChAdOx1 nCov-19 vaccination against SARS-CoV-2, the causative agent of Coronavirus Disease 2019 (COVID-19). The presentation mimicked clinical features of polymyalgia rheumatica and was distinctive in its pattern and delayed onset. Its severity in an elderly patient was significant against trial findings of decreasing reactogenicity of ChAdOx1 nCov-19 vaccine with increasing age, and traumatic to the patient. Acute phase reactants were elevated, consistent with recent similar reports among mostly elderly, female patients. New onset rheumatological conditions and flares of pre-existing, well-controlled conditions had been well established in COVID-19 and, to a lesser extent, post-vaccination. Viral arthralgias as a distinct clinical entity in COVID-19 is only beginning to be recognized. It could be that this case report represents a similar entity which occurs following vaccination against SARS-CoV-2. Despite this, the benefits of vaccination continue to outweigh such risks, although this case report is important for providing understanding of clinical progression when such reactions occur, aiding in patient discussions and clinical decisions to weigh up further investigations or empirical treatment against reassurance and close monitoring.<\/jats:p>","DOI":"10.3390\/vaccines9111220","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T23:27:39Z","timestamp":1634858859000},"page":"1220","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Severe but Self-Limiting Polyarthralgia with Functional Impairment Following ChAdOx1 nCov-19 Vaccination in an Elderly Recipient"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2135-2198","authenticated-orcid":false,"given":"Joel Ern Zher","family":"Chan","sequence":"first","affiliation":[{"name":"Investigator Clinic, Port Lincoln, SA 5606, Australia"},{"name":"Flinders and Upper North Local Health Network, Port Augusta, SA 5700, Australia"},{"name":"Adelaide Medical School, Adelaide, SA 5000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Irimpen","sequence":"additional","affiliation":[{"name":"Investigator Clinic, Port Lincoln, SA 5606, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ymthe.2020.10.002","article-title":"Pros and cons of adenovirus-based SARS-CoV-2 vaccines","volume":"28","author":"Kremer","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_3","unstructured":"Australian Technical Advisory Group on Immunisation (2021, May 27). Joint Statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the Use of COVID-19 Vaccine AstraZeneca. 23 May 2021, Available online: https:\/\/www.health.gov.au\/news\/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.3201\/eid2708.204875","article-title":"Whole-genome sequencing of SARS-CoV-2 from quarantine hotel outbreak","volume":"27","author":"Leong","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33321\/cdi.2021.45.29","article-title":"Repatriation operation in South Australia during the COVID-19 pandemic: Initial planning and preparedness","volume":"45","author":"Meena","year":"2021","journal-title":"Commun. Dis. Intell."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"676843","DOI":"10.3389\/fpubh.2021.676843","article-title":"Recommencement of sport leagues with spectators at the Adelaide Oval during the COVID-19 pandemic: Planning, experience, and impact of a globally unprecedented approach","volume":"9","author":"Chan","year":"2021","journal-title":"Front. Pub. Health"},{"key":"ref_7","unstructured":"World Health Organization (2019). Causality Assessment of an Adverse Event Following Immunization (AEFI): User Manual for the Revised WHO Classification, World Health Organization. [2nd ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.3346\/jkms.2021.36.e245","article-title":"Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination","volume":"36","author":"Hyun","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1016\/S2665-9913(20)30348-9","article-title":"Viral arthritis and COVID-19","volume":"2","author":"Parisi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S2665-9913(20)30396-9","article-title":"First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection","volume":"3","author":"Perrot","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1093\/rheumatology\/keaa691","article-title":"A case of psoriatic arthritis triggered by SARS-CoV-2 infection","volume":"60","author":"Novelli","year":"2021","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41584-020-0448-7","article-title":"Autoimmune and inflammatory diseases following COVID-19","volume":"16","author":"Galeotti","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2665-9913(21)00108-9","article-title":"Flare of rheumatoid arthritis after COVID-19 vaccination","volume":"3","author":"Terracina","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1080\/21645515.2021.1920274","article-title":"Reactive arthritis after COVID-19 vaccination","volume":"17","author":"An","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijid.2021.01.031","article-title":"Viral arthralgia a new manifestation of COVID-19 infection? A cohort study of COVID-19-associated musculoskeletal symptoms","volume":"104","author":"Hoong","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_16","first-page":"1687","article-title":"The development of rheumatoid arthritis after recombinant hepatitis B vaccination","volume":"25","author":"Pope","year":"1998","journal-title":"J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/clinids\/15.2.307","article-title":"Chronic Arthritis after Rubella Vaccination","volume":"15","author":"Howson","year":"1992","journal-title":"Clin. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/11\/1220\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:20:06Z","timestamp":1760167206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/11\/1220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["vaccines9111220"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9111220","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}